MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- NEULAND LABS (pharmaceuticals)
- Latest 8 Quarter Result
NEULAND LABS Quarterly Results (NELB)
Here are the latest quarterly results of NEULAND LABS. For more details, see the NEULAND LABS financial fact sheet and NEULAND LABS share price and chart. For a sector overview, read our pharmaceuticals sector report.
NEULAND LABS Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
3
Dec-19 |
3
Mar-20 |
3
Jun-20 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,687 | 1,715 | 1,727 | 1,810 | 1,862 | 2,036 | 1,919 | 2,054 | |
| Other income | Rs m | 6 | 4 | 13 | 5 | 6 | 10 | 18 | 7 | |
| Turnover | Rs m | 1,694 | 1,719 | 1,740 | 1,815 | 1,868 | 2,046 | 1,936 | 2,061 | |
| Expenses | Rs m | 1,541 | 1,556 | 1,543 | 1,624 | 1,614 | 1,756 | 1,619 | 1,717 | |
| Gross profit | Rs m | 146 | 158 | 184 | 186 | 248 | 281 | 300 | 337 | |
| Depreciation | Rs m | 59 | 74 | 69 | 76 | 83 | 78 | 76 | 89 | |
| Interest | Rs m | 41 | 30 | 47 | 40 | 48 | 57 | 71 | 54 | |
| Profit before tax | Rs m | 53 | 59 | 81 | 75 | 123 | 156 | 171 | 202 | |
| Tax | Rs m | 9 | 13 | 14 | 19 | 38 | 45 | 264 | 51 | |
| Profit after tax | Rs m | 44 | 46 | 67 | 56 | 86 | 110 | -94 | 151 | |
| Gross profit margin | % | 8.7 | 9.2 | 10.7 | 10.3 | 13.3 | 13.8 | 15.6 | 16.4 | |
| Effective tax rate | % | 16.9 | 22.0 | 16.8 | 25.2 | 30.5 | 29.1 | 154.8 | 25.5 | |
| Net profit margin | % | 2.6 | 2.7 | 3.9 | 3.1 | 4.6 | 5.4 | -4.9 | 7.3 | |
| Diluted EPS | Rs | 3.4 | 3.6 | 5.2 | 4.4 | 6.7 | 8.6 | -7.3 | 11.7 | |
| Diluted EPS (TTM) | Rs | NA | NA | NA | 16.6 | 19.9 | 24.9 | 12.4 | 19.7 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
More Pharmaceuticals Company Quarterly Results: WOCKHARDT TORRENT PHARMA ORCHID PHARMA ALEMBIC PHARMA SUVEN LIFESCIENCES
Compare NEULAND LABS With: WOCKHARDT TORRENT PHARMA ORCHID PHARMA ALEMBIC PHARMA SUVEN LIFESCIENCES
Compare NEULAND LABS With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Indian Share Markets Open Higher; HDFC & IndusInd Bank Top Gainers(09:30 am)
Asian stock markets are trading on a positive note today. The Hang Seng is trading up by 0.5% and the Nikkei is trading up by 0.3%.
Views on news
NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)
Sep 2, 2020 | Updated on Sep 2, 2020Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.
More Views on NewsMost Popular
My Latest Stock Recommendation (Fast Profits Daily)
Oct 9, 2020How I picked an exciting stock using trends from both the commodity and equity markets.
The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)
Oct 12, 2020Is ITC an investment or a speculation at current levels?
One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)
Oct 16, 2020The one sector that you should be looking at to make good profits.
The Inflection Point for Defence Stocks is Getting Closer (Profit Hunter)
Oct 9, 2020Few Indian defence companies could use their engineering capabilities to eventually become global leaders.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
NEULAND LABS SHARE PRICE
Oct 21, 2020 10:16 AM
TRACK NEULAND LABS
- Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NEULAND LABS
NEULAND LABS - STRIDES PHARMA SCIENCE COMPARISON
COMPARE NEULAND LABS WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.